Across UC Berkeley, researchers have redirected their investigations to address the challenges of the COVID-19 crisis. Learn about all the ways our experts are offering solutions across disciplines.
University technology transfer has made a significant contribution to fighting COVID-19 while ensuring global access (Healthcare Policy 17(4) May 2022). For example, UC Berkeley, which started incorporating global health provisions in its license agreements as early as 2003 to facilitate affordable access to its innovations in low- and middle-income countries, discovered a new implementation of CRISPR. The inclusion of global health protection terms when licensing the technology to Mammoth Biosciences led to the development of a high throughput COVID-19 test, whiich was granted emergency use authorization by the FDA in January 2022.
Photo courtesy of Max & Jules Photography.
The Office of Intellectual Property and Industry Research Alliances is seeking partners and resources to accelerate UC Berkeley’s extraordinary, communal efforts to understand and mitigate the impacts of the new coronavirus. Below, you'll find special licensing resources to incentivize rapid utilization of UC Berkeley technologies related to COVID-19, as well as examples of how UC Berkeley is partnering with industry to mitigate this pandemic.
Please contact IPIRA for information related to:
For campus policies and resources related to COVID-19, incuding health and safety information, see UC Berkeley's response to the coronavirus outbreak and find guidance on research operations and continuity planning.